RLAY is on the move, up 24%

Relay Therapeutics, Inc. (RLAY) is trading 24% higher at $31.345 today. The stock is rapidly outshining peers on a cheerful day for the Health Care sector.

According to Globe Newsire:

Data from the ReFocus trial for RLY-4008 has been selected for an oral presentation at the upcoming European Society of Medical Oncology (ESMO) Congress, being held September 9-13, 2022. The presentation will focus on dose escalation and dose expansion patients with FGFR2 fusion, FGFR inhibitor-naïve cholangiocarcinoma. Relay Therapeutics will host a conference call on September 12, 2022 at 8:00 am E.T. to discuss the results of the presentation.

Relay Therapeutics, Inc. has been trading between a 52-week high of $38.15 and a 52-week low of $12.65. The stock has a market cap of $3.41 Billion.

Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer.